Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Negocios · 9/4/20141 min de lectura
Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use; Draft Guidance for Industry and Food and Drug Administration Staff; Extension of Comment Period
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is extending to May 7, 2014, the comment period for the notice that appeared in the Federal Register of January 7, 2014 (79 FR 830). In the notice, FDA requested comments on a draft guidance document entitled "Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use." The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.
Idioma original de la fuente: Federal Register — Food and Drug AdministrationAbrir el comunicado original →